News
MESO
13.61
-4.29%
-0.61
Weekly Report: what happened at MESO last week (0928-1002)?
Weekly Report · 1d ago
Weekly Report: what happened at MESO last week (0921-0925)?
Weekly Report · 09/28 10:17
Analysts Offer Insights on Healthcare Companies: Arcus Biosciences (RCUS) and Mesoblast (MESO)
TipRanks · 09/25 15:40
Mesoblast Receives FDA Approval To Implement A New Potency Assay, T-Cell Proliferation Inhibition Bioassay, For Release And Stability Monitoring Of All New Commercial Product Lots Of Its Mesenchymal Stromal Cell Product Ryoncil
Benzinga · 09/24 11:06
Weekly Report: what happened at MESO last week (0914-0918)?
Weekly Report · 09/21 10:17
FDA, Duke-Margolis workshop to examine evidence standards for rare diseases
Seeking Alpha · 09/20 18:57
Weekly Report: what happened at MESO last week (0907-0911)?
Weekly Report · 09/14 10:23
Weekly Report: what happened at MESO last week (0831-0904)?
Weekly Report · 09/07 10:16
Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX) and Mesoblast (MESO)
TipRanks · 09/04 12:10
Jefferies Keeps Their Buy Rating on Mesoblast Limited (MEOBF)
TipRanks · 08/31 12:16
Weekly Report: what happened at MESO last week (0824-0828)?
Weekly Report · 08/31 10:23
Post-Approval Safety Risks Threaten Mesoblast’s Ryoncil Commercialization in Fragile Pediatric SR-aGVHD Market
TipRanks · 08/31 06:07
Mesoblast Earnings Call: RYONCIL Fuels Growth Story
TipRanks · 08/30 00:11
*Mesoblast Price Target Cut 3.3% to A$2.90/Share by Jefferies
Dow Jones · 08/27 21:30
Piper Sandler Reiterates Overweight on Mesoblast, Raises Price Target to $39
Benzinga · 08/27 17:25
Mesoblast FY EPS $(0.04) Misses $0.01 Estimate, Sales $120.250M Beat $66.000M Estimate
Benzinga · 08/27 13:00
Mesoblast price target raised to $39 from $35 at Piper Sandler
TipRanks · 08/27 10:45
Full Transcript: Mesoblast FY 2026 Earnings Call
Benzinga · 08/26 23:25
Mesoblast Reports Substantial Revenue Growth to US$120M
Barchart · 08/26 19:32
Here are the major earnings after the close Wednesday
Seeking Alpha · 08/26 14:00
More
Webull provides a variety of real-time MESO stock news. You can receive the latest news about Mesoblast through multiple platforms. This information may help you make smarter investment decisions.
About MESO
Mesoblast Limited is an Australia-based biotechnology company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company's Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: Chronic heart failure (CHF) and Chronic low back pain (CLBP) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.